A note on post-marketing safety study design to characterise time-dependent adverse events

被引:1
|
作者
Narukawa, Mamoru
Yafune, Akifumi
机构
[1] Kitasato Univ, Grad Sch, Div Pharmaceut Med, Tokyo, Japan
[2] Clin Sendagaya, Tokyo, Japan
关键词
safety study design; time-dependent adverse events; Weibull model;
D O I
10.1002/pds.1472
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To investigate a suitable post-marketing safety study design, that is number of patients and duration of exposure, to well characterise adverse events (AEs) profiles under limited resources, fixed patient-months. Methods A simulation study is conducted to investigate a suitable study design that can appropriately characterise the shape of the hazard function of AEs using the Weibull model. The reliability of the estimates is evaluated by referring their bias and mean squared error (MSE). Results In general, patients should be followed for a longer period even if the number of patients is relatively small for characterising delayed AEs. Patients' drop-out affects the estimation and deteriorates its reliability. For AEs that are likely to occur soon after the exposure, a study with relatively shorter duration and large number of patients is preferable. Conclusions It is important to evaluate statistically the appropriate study design in planning a safety study so that a good estimate of the hazard function would be obtained. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:1146 / 1152
页数:7
相关论文
共 50 条
  • [41] Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database
    Yu, Zhe
    Luo, Jing
    Wei, Hongshan
    [J]. HELIYON, 2024, 10 (06)
  • [42] The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England
    Twaites, Beverley R.
    Wilton, Lynda V.
    Shakir, Saad A. W.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2007, 21 (04) : 392 - 399
  • [43] A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer
    Masuishi, Toshiki
    Nagaoka, Soshi
    Jin, Long
    Yoshizawa, Kenichi
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (04) : 1701 - +
  • [44] Enhancing the Presentation and Evaluation of Cumulative Post-Marketing Safety Data: A Pilot Study
    Gilchrist, A.
    Layton, D.
    Fogg, C.
    Shakir, S.
    [J]. DRUG SAFETY, 2011, 34 (10) : 968 - 968
  • [45] Safety and Effectiveness of Varenicline in Korean Smokers: A Nationwide Post-Marketing Surveillance Study
    Ra, S.
    Shin, J.
    Ock, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [46] Enhancing the Presentation and Evaluation of Cumulative Post-Marketing Safety Data; a Pilot Study
    Gilchrist, Anna
    Layton, Deborah
    Fogg, Carole
    Shakir, Saad
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S338 - S339
  • [47] Safety and Effectiveness of Varenicline in Korean Smokers: A Nationwide Post-Marketing Surveillance Study
    Ock, Minsu
    Shin, Ji Soo
    Ra, Seung Won
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 413 - 426
  • [48] Efficacy and safety of valsartan in hypertensive Taiwanese patients: Post-marketing surveillance study
    Liou, Chia-Wei
    Yeh, Tung-Chen
    Chen, I-Chung
    Huang, Chi-Hung
    Hung, Yi-Jen
    Hsu, Kwan-Lih
    Lee, Jian-Der
    Lei, Meng-Huan
    Chang, Kuan-Cheng
    Liao, Pei-Yung
    Chen, Zhih-Cherng
    Wang, Jackson
    Hou, Charles Jia-Yin
    [J]. BLOOD PRESSURE, 2011, 20 : 13 - 21
  • [49] Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system
    Ding, Yiling
    Su, Hongyan
    Shu, Yamin
    Chen, Jing
    [J]. HELIYON, 2024, 10 (09)
  • [50] SAFETY AND ADVERSE EVENT PROFILE OF TUMOR TREATING FIELDS IN ANAPLASTIC GLIOMA A POST-MARKETING SURVEILLANCE ANALYSIS
    Tran, David
    Kesari, Santosh
    Bota, Daniela A.
    [J]. NEURO-ONCOLOGY, 2018, 20 : 217 - 217